Gibson Dunn & Crutcher advised Spyre Therapeutics, Inc. on the offering, and Covington & Burling advised the underwriters. Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised 89bio, Inc. on the offering, and Cooley advised the underwriters. 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced the...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Jade Biosciences on the transaction, and Cooley advised the placement agents; while Goodwin Procter advised Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Sidley Austin is advising GlycoMimetics, Inc. on the transaction, and Gibson, Dunn & Crutcher is advising Crescent Biopharma, Inc. GlycoMimetics, Inc. (NASDAQ: GLYC) announced it has...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Fairmount Funds on the deal. Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or the “Company”), a clinical-stage pharmaceutical company, announced the pricing...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Alcon Inc. on the deal, and Morrison & Foerster advised OcuMension Therapeutics. OcuMension Therapeutics (“OcuMension”), a Hong Kong-listed, China-based ophthalmic pharmaceutical...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is advising ARCA biopharma, Inc. on the transaction, while Gibson, Dunn & Crutcher is advising Oruka Therapeutics and Cooley is advising...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher represented Apogee Therapeutics, Inc. in the offering, and Cooley represented the underwriters. Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company, announced the...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP represented Dianthus Therapeutics, Inc. on the placement. Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP is advising Nextech on the matter. Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP is advising Arrowhead Pharmaceuticals, Inc. on the offering. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced the pricing of an underwritten registered offering...
You must be a Standard 1 Year member to access this content.
Leerink Partners is acting as exclusive financial advisor and Gibson, Dunn & Crutcher LLP is acting as legal counsel to Rain. Goodwin Procter LLP is acting...
You must be a Standard 1 Year member to access this content.
